These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36912019)

  • 21. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
    Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
    Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
    J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre.
    Isah A; Chukwu PO; Abba A; Igboeli NU; Ebere A; Omotola OF; Alozie FA; Ekwunife OI; Adibe MO
    Afr Health Sci; 2023 Mar; 23(1):157-169. PubMed ID: 37545946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials.
    Ford N; Shubber Z; Pozniak A; Vitoria M; Doherty M; Kirby C; Calmy A
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):422-9. PubMed ID: 25850607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.
    Curtis L; Nichols G; Stainsby C; Lim J; Aylott A; Wynne B; Clark A; Bloch M; Maechler G; Martin-Carpenter L; Raffi F; Min S
    HIV Clin Trials; 2014; 15(5):199-208. PubMed ID: 25350958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults.
    Li J; Chen D; Wen Z; Du Y; Huang Z; Zhong H; Wang Y; Yin S
    Medicine (Baltimore); 2022 Oct; 101(42):e31100. PubMed ID: 36281149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection.
    Chan P; Yoon B; Colby D; Kroon E; Sacdalan C; Sriplienchan S; Pinyakorn S; Ananworanich J; Valcour V; Vasan S; Hsu D; Phanuphak N; Paul R; Spudich S
    Clin Infect Dis; 2023 Feb; 76(3):e718-e726. PubMed ID: 35687498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rolling out Efavirenz for HIV Precision Medicine in Africa: Are We Ready for Pharmacovigilance and Tackling Neuropsychiatric Adverse Effects?
    Masimirembwa C; Dandara C; Leutscher PD
    OMICS; 2016 Oct; 20(10):575-580. PubMed ID: 27627692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
    Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
    Leutscher PD; Stecher C; Storgaard M; Larsen CS
    Scand J Infect Dis; 2013 Aug; 45(8):645-51. PubMed ID: 23427878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
    Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
    Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania.
    Fimbo A; Mwalwisi YH; Mwamwitwa K; Matiko D; Mfinanga E; Lyimo J; Sabasaba A; Missago S; Bukundi E; Gotora G; Respick D; Nkayamba A; Masunga E; Mnkugwe RH; Kunambi PP; Munishi C; Musanhu CC; Minzi OMS; Mlugu EM
    Sci Rep; 2024 Jan; 14(1):615. PubMed ID: 38182720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibitor-containing first-line antiretroviral therapy in Pune, India.
    Dravid A; Betha TP; Sharma AK; Gawali R; Mahajan U; Kulkarni M; Saraf C; Kore S; Dravid M; Rathod N
    HIV Med; 2020 Oct; 21(9):578-587. PubMed ID: 33021066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
    Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
    Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
    [No Abstract]   [Full Text] [Related]  

  • 38. Health-related quality of life among HIV-infected patients initiating treatment in Brazil in the single-tablet regimen era.
    Costa JO; Pearson SA; Acurcio FA; Bonolo PF; Silveira MR; Ceccato MDGB
    AIDS Care; 2019 May; 31(5):572-581. PubMed ID: 30727749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropsychiatric Adverse Events Following Antiretroviral Therapy in People Living with HIV: A Real-World Study of Dynamic Trends and Risk Factors in Hangzhou, China.
    Zhang W; Wang Y; Li E; Yan D; Yu J; Zhu M; Shi J; Zheng L
    Infect Drug Resist; 2023; 16():5007-5019. PubMed ID: 37551279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells.
    George JW; Mattingly JE; Roland NJ; Small CM; Lamberty BG; Fox HS; Stauch KL
    Front Immunol; 2021; 12():639378. PubMed ID: 34093527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.